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Abstract
Background: Thymomas represent an uncommon and heterogeneous group of intrathoracic malignancies which
require different treatments corresponding to their individual tumor stage. The objective of this study was to review
the efficacy of our applied stage-based treatment for thymoma in due consideration of thymectomy.
Methods: This is a single-center, institutional review board-approved retrospective study of 50 consecutive patients
with thymoma treated at our division within 10 years.
Results: There were 29 women (58 %) and 21 men (42 %), mean age 58.3 years. Twenty nine (58 %) had clinical
symptoms and 14 (28 %) had myasthenia gravis. Forty-five patients (90 %) underwent thymectomy and complete
resection was done in 42 cases (93.3 %). Histologic results were 6 subtype A, 5 AB, 8 B1, 12 B2, 12 B3, and 7 C. The
Masaoka staging system revealed 20 stage I, 18 stage II, 6 stage III, and 6 stage IV. Two patients had neoadjuvant
therapy and 25 received postoperative treatment. Five (11.1 %) had tumor recurrence, treated with re-resection. The
5-year disease-free survival was 91.5 %. Two patients died of tumor progression and three died of other causes (10 %).
The 5-year overall survival was 82.3 % and the median survival time was 92.1 months. The 5-year survival rate after
thymectomy was 87.2 % and the median survival was 92.1 months.
Conclusions: Complete resection still remains the mainstay in the treatment of non-metastatic thymoma and should
be performed whenever feasible. Close multidisciplinary teamwork is mandatory to optimize the neurologic outcome
and to prolong postoperative survival.
Keywords: Thymoma, Surgery, Thymectomy, Myasthenia gravis, Survival
Background
Thymomas, which originate from the epithelial cells of the
thymus, are uncommon thoracic malignancies with an an-
nual incidence of 0.15/100,000 persons. Thymomas are
the most common tumors of the anterior mediastinum,
representing 50 % of all cases in adults [1, 2]. Thymomas
develop among all ages with a mean age of about 53 years
[1]. There is nearly an equal gender distribution, although
myasthenia gravis (MG) seems to occur more frequently
in the younger collective and among female patients [3].
In one third of all cases, thymomas cause no clinical
symptoms. Clinical symptoms develop due to tumor
growth with subsequent compression, expulsion, or infil-
tration of the surrounding organs. MG, representing the
most commonly associated parathymic syndrome, develops
in one third of the cases [4]. In general, thymomas usually
grow slowly. With increasing malignant potential, they
grow rapidly and have a tendency to infiltrate surrounding
tissues as well as locally spread mainly to the pleura, the
pericardium, and the lungs. Distant metastases are uncom-
mon and almost confined to the liver and the bones. More-
over, thymomas have a tendency for late local recurrence
even after complete thymectomy [3, 5].
Even though thymic carcinomas are designated as type
C tumors according to the World Health Organization
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(WHO) criteria, they are still different from thymomas
[1]. They present a distinct group associated with high
malignancy and therefore more aggressive behavior.
Thymic carcinomas frequently attempt to infiltrate the
surrounding tissue and metastasize to regional lymph
nodes as well as distant sites [1, 3]. Due to the fact that
thymic carcinomas represent a heterogeneous group
with very low incidence (<10 % of thymic neoplasms)
[3], they are not specially outlined in this study which
focuses generally on the treatment and outcome of
thymomas in general according to WHO criteria.
In particular in local advanced disease of thymoma,
the multidisciplinary approach consisting of thymectomy,
chemotherapy, and radiotherapy gains increasing import-
ance [1–3].
Therefore, the objective of our study was to review the
efficacy of our applied stage-based treatment for thymoma
in due consideration of thymectomy.
Methods
Patients
Between 2003 and 2013, 51 consecutive patients suffering
from histologically proven thymoma were treated at our
division. One patient with thymoma subtype AB, who was
not fit for surgery, died from pneumonia 3 months after
diagnosis and was therefore excluded from the study. Fi-
nally, the complete records of 50 patients were available for
evaluation and included into this study.
In particular, patient’s age, gender, functional assessment,
the incidence of pre- and postoperative MG, clinical symp-
toms, histology, tumor staging, surgical aspects, complica-
tions, postoperative therapy, tumor recurrence, and
disease-free survival (DFS) as well as overall survival (OS)
were assessed. The data were collected prospectively in the
database of the hospital and evaluated retrospectively. Sur-
vival data were obtained from the medical records and the
database, by telephone interview with the patients and
their family doctor, or by contacting the responsible
registry office. However, OS was defined as the time from
the date of surgery to the date of death or the date of last
contact alive, respectively. DFS was calculated from the
date of surgery to the date of diagnosis of tumor recur-
rence. This study was approved by the local ethics commit-
tee of the Medical University of Graz (number: 25-548 ex
12/13). As this is a retrospective non-intervention study,
the institutional review board waived the need for written
informed consent from the patients.
Functional evaluation of the patients included echocar-
diogram, cardiac ultrasound, and spiroergometry. The
oncological staging consisted of chest X-ray; computed
tomography (CT scan) of the thorax, the mediastinum,
and the abdomen; and positron emission tomography-
CT (PET-CT). Moreover, every patient, irrespective of
underlying MG, was provided with neurological investi-
gation before initiation of treatment.
Preoperative tumor biopsy enabling adequate staging
was performed in the majority of patients. The histological
assessment was done according to the commonly used
WHO criteria [6].
In those patients with clearly visible encapsulated tumor
of small or moderate size, the biopsy was not required.
Preoperative tumor biopsy was performed in cases with
strong suspicion of high malignancy corresponding to
thymic carcinoma, in case of tumorous infiltration, and to
rule out mediastinal lymphoma.
Specific treatment
Based on both, the histologic results of the tumor biopsy
and the CT scan, the preoperative tumor stage was assessed
according to the most widely used Masaoka staging system
[7], which still represents the chief staging criteria for thym-
omas. The patients underwent further specific treatment
tailored to their particular tumor stage according to the
decision made within the local interdisciplinary tumor
board.
In case of local disease with completely encapsulated
thymoma corresponding to Masaoka stages I and II, the
patients were immediately provided with complete surgical
resection.
In case of locally advanced disease corresponding to
Masaoka stage III with high suspicion of tumorous infiltra-
tion into the surrounding tissue, neoadjuvant chemother-
apy and/or radiotherapy was scheduled.
However, in case of very advanced disease with distant
metastases corresponding to Masaoka stage IVB, surgery
was not indicated and palliative chemotherapy and/or
radiotherapy was therefore scheduled.
Thymectomy
Thymectomy was performed using three surgical tech-
niques: the trans-sternal and the trans-thoracic thymec-
tomy represented the open approaches. The minimally
invasive technique, video assisted thorascopic surgery
(VATS), was also employed.
The trans-sternal approach was primarily provided for
large-sized tumors, tumors with histologically proven
high-grade malignancy, thymic carcinoma, radiologically
verified broad tumorous adherence to adjacent struc-
tures expecting extended resection, and strong suspicion
of tumor infiltration (locally advanced disease) and pre-
ceded neoadjuvant treatment.
The trans-thoracic approach was done in the minority
of all cases. It was provided for completely encapsulated
thymomas of large size strictly located in one hemithorax.
Moreover, this approach was also used after anterior para-
sternal mediastinotomy for subsequent ipsilateral thymec-
tomy within the same surgical intervention.
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The minimally invasive approach, single-sided or double-
sided VATS, was provided for completely encapsulated
thymomas of small or medium size without evidence of
tumor infiltration and without neoadjuvant therapy. Besides
those facts, intraoperative conversion to the open approach
was required in case of complication, technical failure, large
tumor size, deficient overview, dense adhesions, or due to
unexpected locally advanced disease with perithymic
invasion.
Trans-sternal approach
After median sternotomy, the entire anterior mediastinum
was visualized. The phrenic was clearly identified on each
side, and meticulous dissection was started on the left side
at the lower border of the tumor onto the pericardium at
the diaphragmatic sulcus, respectively. The dissection was
continued along the course of the left phrenic nerve
towards the innominate vein. Care was taken not to dam-
age the phrenic nerve. Blunt dissection was continued
onto the anterior and lower circumference of the innom-
inate vein. The originating thymic veins were clipped, and
dissection was continued towards the superior vena cava.
After mobilization of the superior portion of the thym-
oma, further dissection was continued along the course
of the contralateral phrenic nerve until the diaphragm
was reached. The entire thymoma, along with the residual
four lobes of the thymus, associated with the mediastinal
and pericardial as well as diaphragmatic fat pad, was
resected en bloc. Finally, the extent of the en bloc resec-
tion represented the area between the course of both
phrenic nerves as well as from the diaphragm to the thy-
roid gland, respectively.
In the case of local advanced disease with tumor infiltra-
tion into neighboring organs and tissues, extended resec-
tion of those affected structures was required. Removal of
tumor infiltration into the adjacent lung parenchyma was
accomplished by wedge resection using mechanical staple
devices.
In case of involvement of the innominate vein, the af-
fected part of the vascular wall was tangentially resected
and tight sutures were applied.
In case of partial pericardial and/or diaphragmatic resec-
tion, the defect was closed using synthetic prostheses
(GORE-TEX®, Flagstaff, AZ, USA) which were fixed with
interrupted single-knot sutures. Furthermore, the pericar-
dial patch was fenestrated to avoid postoperative cardiac
tamponade.
VATS approach
After maintenance of required single lung ventilation,
three trocars, located at the typical positions, were
inserted through the appropriate hemithorax and the as-
certainable part of the mediastinum was visualized. The
minimal-invasive dissection was performed in the same
manner as mentioned above. After complete dissection,
the resected specimen was placed into a bag and removed
through the port. In case of larger tumor size associated
with thymic branches reaching the contralateral pleura
requiring bilateral VATS, the minimal-invasive approach
was stopped after sufficient tumor dissection at the first
site and the ports were closed as mentioned above. The
VATS procedure was immediately repeated in the same
manner on the contralateral side completed by successful
retrieval of the en bloc-resected specimen within the bag
through the port.
Trans-thoracic approach
After maintenance of required single lung ventilation,
the chest was opened through a muscle-sparing antero-
lateral mini-thoracotomy. After visualization of the medi-
astinum, en bloc resection was performed as mentioned
in the trans-sternal approach.
Postoperative follow-up
After thymectomy, the decision concerning the adequate
postoperative treatment based on Masaoka staging [7]
was made within our local multidisciplinary tumor board
consisting of thoracic surgeons, oncologists, radiothera-
pists, and pathologists. In the majority of cases, the
oncological follow-up consisting of thoraco-abdominal
CT scan was scheduled every 6 months for the first two
postoperative years, and then annually for the following
3 years.
Results
Among those 50 patients, the slight majority were women
(58 %). The mean age was 58.3 years (range 22–82 years).
At the time of admission, 29 patients (58 %) complained
about symptoms.
Preoperative tumor biopsy was performed in the major-
ity of patients, carried out by CT scan-guided fine needle
aspiration (N = 12) or by using anterior parasternal med-
iastinotomy (N = 14), thoracoscopy (N = 5), muscle-sparing
mini-thoracotomy (N = 3), or mediastinoscopy (N = 1),
respectively.
At the time of diagnosis, 39/50 patients (78 %) had no
suspicion of locally advanced disease. Distant metastases
at one or more sites were diagnosed in five patients
(10 %) affecting the lung, the bones, and the pleura.
Neoadjuvant therapy, due to considerable local tumor infil-
tration, was administered in two out of those five patients
(chemotherapy and chemoradiation).
Thymectomy was performed in 90 % of all patients.
Extended resection due to locally advanced disease was
required in 5/45 patients (11.1 %). The affected struc-
tures were lung, pericardium, phrenic nerve, innominate
vein, and parietal pleura. However, intraoperative con-
version from the VATS procedure to the open approach
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was required in seven cases. Among those 45 patients
who had undergone surgery, 25 (55.6 %) received adju-
vant treatment.
Histologic examination according to the WHO cri-
teria revealed thymoma B2 and B3 as the predominat-
ing histologic subtype. Tumor staging according to the
Masaoka system yielded stage I as the most frequent
stage. The mean shortest diameter of the resected spe-
cimen was 6.5 cm (ranged 2.0 to 15.0 cm), whereas the
mean largest diameter revealed 8.7 cm (ranged 4.0 to
19.0 cm). The mean volume was 357.1 cm3 (median
221.3 cm3). These clinicopathological parameters men-
tioned above are summarized in detail in Table 1.
There was no 30-day mortality. However, seven patients
(14 %) developed complications. Intraoperative bleeding
occurred in three patients, postoperative ipsilateral pleural
empyema in one, progressive mediastinal and soft tissue
emphysema in one, and pneumonia in two.
Five (11.1 %) patients out of 45 who had undergone
thymectomy developed tumor recurrence. The mean DFS
was 58.4 months (ranged 28–77 months). The 5-year DFS
was 91.5 %. Up to the end of this study, four of them are
still alive; one patient died 92 months after thymectomy
due to heart failure. A detailed survey of these 50 patients
containing their different treatment modalities according
to Masaoka stage is given in Table 2.
Palliative therapy was administered in six patients. De-
finitive radiotherapy due to local inoperability was ap-
plied in one case, definitive chemoradiotherapy was
done in one patient, and chemotherapy as solo treat-
ment was performed in four patients.
The 5-year OS was 82.3 % and median survival time
was 92.1 months (95 % CI 81.8 to 102.3). The 5-year
survival rate after thymectomy was 87.2 % and the cor-
responding median survival was 92.1 months (95 % CI
81.8 to 102.3). No patient was lost to follow-up.
Tumor histology, tumor volume, Masaoka stages I to
III, and MG had no significant influence on patient’s sur-
vival. At the end of follow-up, 5 out of 50 patients
(10 %) had died, whereas only 2 deaths (Masaoka III and
IV) were cancer-related. These two patients died after
13 and 12 months, respectively.
Table 1 Detailed clinicopathological parameters of 50 patients
with thymoma





Retrosternal pressure 6 12





Involuntary weight loss 4 8
Superior vena cava syndrome 2 4
Myasthenia gravis 14 28
Diagnostics
CT scan 50 100
PET-CT 25 50








R0 resection 42 93
R1 resection 2 5
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Discussion
The correct treatment of thymoma is different in relation
to the pre-therapeutic tumor staging. Surgical resection is
of utmost importance in the therapy of non-metastatic
thymoma [1]. Chemotherapy and radiotherapy represent
further supportive treatment modalities which are applied
depending on the individual tumor stage [1, 2].
Preoperative patient selection is indispensable for the
appropriate surgical approach. Median sternotomy was
the dominant technique in this present analysis which is
confirmed by most authors [5]. Although the open tech-
nique was used in the majority of patients, we share the
argument that VATS-thymectomy is a safe approach
achieving comparable results in case of small thymomas
without perithymic invasion [8]. Therefore, excellent 5-
and 10-year survival rates are reported for resected early-
stage thymomas [3, 4]. Complete thymectomy, early-stage
disease, and the WHO classification are factors respon-
sible for long-term DFS and better OS [9, 10]. However,
these data are in pleasant accordance with our results.
In case of locally advanced disease corresponding to
Masaoka III, immediate thymectomy is often precluded
and the multimodal approach is demanded [2, 11, 12].
In our opinion, the adequate decision should not be made
by the thoracic surgeon alone. There is more responsibil-
ity required emphasizing the need for an interdisciplinary
tumor board which should address all different aspects
related to each individual case as it was already done in
our cohort of patients.
In the present study, 25 patients (55.6 %) received adju-
vant treatment after surgery [13]. Although there is evi-
dence that a complete resection obviates the need for
adjuvant radiotherapy in early-stage disease [3], in our col-
lective, all thymoma stage II underwent postoperative
radiation to prevent tumor recurrence as good as possible
[14]. In the case of Masaoka stage III, adjuvant therapy
was administered due to clear evidence supporting the
impact of postoperative radiation [1, 2].
Postoperative tumor recurrence still remains a serious
problem. Tumor histology, Masaoka stage, completeness
of resection, and the tumor size have been identified as
independent predictors of recurrence [15], showing recur-
rence rates for Masaoka stages II and III between 16 and
26 %, respectively. In our collective, 11 % of the patients
had tumor recurrence after a mean DFS of 58.4 months
which is in line with recent literature [3, 4]. Among these
five patients, tumor recurrence was to be found intratho-
racic, confined to the pleura in all cases, although postop-
erative radiotherapy had been administered. There were
neither lymph node metastases nor lung metastases. Sur-
gical management of the recurrence is the treatment of
choice [2] and is associated with better outcome com-
pared to non-surgical therapy [16, 17]. In our current ana-
lysis, all patients with tumor recurrence were amenable to
complete re-resection. However, up to the end of follow-
up, one patient died not related to tumor, whereas the
remaining four patients are still alive showing no evidence
of progression of disease.
It is a matter of fact that associated MG represents a cru-
cial cofactor in approximately 25–33 % of the patients with
thymoma influencing considerably the perioperative course
[4, 18]. Therefore, every patient in our collective had to
undergo preoperative neurologic investigation. In particu-
lar, those patients with preoperative MG (N = 14; 28 %)
were identified and specific medication was administered
according to the suggestion given by the neurologist. After
thymectomy, MG subsided continuously except in one
case. Our remission rate (92.9 %) is in line with the results
reported after extended trans-sternal thymectomy [18]
underlining the imperative necessity for both meticulous
resection and the close teamwork between thoracic sur-
geon and neurologist in order to optimize the neurologic
outcome. In contrast, the incidence of postoperative MG
appearing for the first time is considerably less showing up
with 1–3 % [19]. The detailed mechanism of this rare and
delicate phenomenon remains unclear and is still a matter
of debate [20]. In our collective, post-thymectomy MG was
diagnosed in only three patients, showing no evidence of
preoperative MG. Complete remission could be obtained
in two of them by administration of anticholinesterase
drugs combined with corticosteroids, plasmapheresis, and
immunoglobulin therapy. In the third case, additional
redo-surgery with extended resection of all remaining
mediastinal fat was done. In this context, extended open
thymectomy for patients even without preoperative MG is
still recommended [18, 19].
Table 2 Survey of 50 patients containing their different treatment modalities according to Masaoka stage
Masaoka Total number Biopsy Neoadjuvant treatment Sternotomy VATS Thoracotomy Adjuvant radiation Recurrence Death
I 20 13 11 7 4 2
IIA 15 9 10 6 1 14 3 2
IIB 3 1 2 2 1 3
III 6 6 1 5 1 2 1
IVA 1 1 2 1 5
IVB 5 5 1 2
VATS video-assisted thoracic surgery
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For the sake of completeness, the significance of thymic
carcinoma should be briefly discussed at this point. It is
beyond all question that complete thymectomy is the
mainstay of treatment for non-metastatic thymic carcin-
oma to maintain disease control and for the prolongation
of survival [21, 22], particularly in the early Masaoka
stages [23]. In contrast, the value of supportive therapy re-
mains controversial. Whereas some authors have second
thoughts concerning the benefit of chemotherapy and
radiotherapy [21], other experts conclude that long-term
survival can be ensured using a multimodality treat-
ment [22]. Although the number of thymic carcinomas
in this study is too small to draw serious conclusions
(N = 7), their stage-based multimodal treatment was
done according to these recent recommendations given
by the local tumor board. At the end of follow-up, two
of these seven patients had died, whereas only one
death was related to tumor progression.
Finally, there are two limitations regarding our
current study we want to address. The relatively short
time period may represent the first limit, whereas the
retrospective nature of the study is the second draw-
back. This situation is hardly avoidable due to the
rarity of the investigated disease (resulting in a small
number of patients), in particular in a comparatively
small country.
Conclusions
Nevertheless, we are able to corroborate that thym-
ectomy still remains the mainstay in the treatment
of non-metastatic thymoma and should therefore be
performed whenever feasible. Complete resection is
definitely essential for disease control and long-term
survival of patients. Thus, meticulous surgery with
complete removal of the thymus gland and the asso-
ciated fat is required in order to prevent tumor
recurrence and postoperative MG, respectively. We
want to emphasize that close multidisciplinary team-
work between thoracic surgery, oncology, radiotherapy,
and neurology is mandatory in order to optimize the
neurologic outcome and to prolong postoperative
survival.
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